Proliferative retinopathies, such as those complicating prematurity and diabetes, are major causes of
blindness. A prominent feature of these retinopathies is excessive neovascularization, which is orchestrated by the
hypoxia-induced
vascular endothelial growth factor (
VEGF) stimulating endothelial cells and the
integrin-mediated adhesive interactions of endothelial cells with extracellular matrix components such as
fibronectin (FN). Recently, we demonstrated that
alpha-defensins interfere with alpha5beta1-FN interactions and dependent endothelial cell functions. Here,
alpha-defensins were studied in
hypoxia-induced proliferative retinopathy. In vitro,
alpha-defensins specifically inhibited alpha5beta1-integrin-dependent migration of bovine
retinal endothelial cells (BRECs) to FN, attenuated the
VEGF-stimulated increase in endothelial permeability, and blocked BREC proliferation and capillary sprout formation in 3-dimensional
fibrin-matrices. An up-regulation of beta1-integrin and FN was observed in the retinal vessels in the mouse model of
hypoxia-induced
retinal angiogenesis. Systemic and local administration of
alpha-defensins reduced
retinal neovascularization by 45% and 60%, respectively, and this effect was comparable to the inhibitory effect of alpha5beta1-blocking antibody.
alpha-Defensins were detected in human diabetic retinas associated with normal retinal vessels but were absent from proliferative lesions. Together, these data show that
alpha-defensins inhibit pathologic
retinal neovascularization in vivo and may provide a clinically efficient strategy against proliferative retinopathies.